Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL4297843

TORIPALIMAB
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
No structure available
ChEMBL ↗

Basic Information

ChEMBL ID CHEMBL4297843
Name TORIPALIMAB
Phase Approved
Structure Type SEQ
Therapeutic ✓ Yes

Known Names

Anti-pd-i mab-shanghai junshi CHS-007 Js-001 Js001 Loqtorzi TAB-001 TAB001 Teriprizumab Toripalimab Toripalimab-tpzi Treprizumab Tripleitriumab +2 more
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
14
Known Names
20
Indications
1
Mechanisms

Drug Information

Molecule Type Antibody
First Approval 2023
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Parenteral
USAN Stem -mab
USAN Year 2021

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Programmed cell death protein 1 antagonist ANTAGONIST Programmed cell death protein 1 ✓ ✓

Indications

Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma Neoplasms Neoplasms Adenocarcinoma Carcinoma, Hepatocellular Carcinoma, Neuroendocrine Carcinoma, Non-Small-Cell Lung Cholangiocarcinoma Cholangiocarcinoma Esophageal Neoplasms Esophageal Neoplasms Esophageal Neoplasms Hodgkin Disease Lymphoma Melanoma Melanoma Melanoma Nasopharyngeal Neoplasms Small Cell Lung Carcinoma

ATC Classification

L01FF13
toripalimab
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS

Data from ChEMBL 36 via Core Engine